← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Athira Pharma, Inc.
Bothell, WA
$15,227,987
Total funding
1
Grants
Funding over time
peak $7.8M · FY2020–22$10M$7.5M$5M$2.5M$0
'20
'21
'22
Funding mix
By agency
NIH$15,227,987 · 1
By mechanism
R01$15,227,987 · 1
Investigators at Athira Pharma, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A randomized, placebo-controlled, double-blind study to evaluate safety and efficacy of NDX-1017 treatment in Alzheimer's dementia patients$7,811,344
R01 · FY2020 · AG
A randomized, placebo-controlled, double-blind study to evaluate safety and efficacy of NDX-1017 treatment in Alzheimer's dementia patients$4,489,665
R01 · FY2021 · AG
A randomized, placebo-controlled, double-blind study to evaluate safety and efficacy of NDX-1017 treatment in Alzheimer's dementia patients$2,926,978
R01 · FY2022 · AG